期刊
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
卷 52, 期 -, 页码 76-83出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2016.01.027
关键词
Apoptosis; Human pluripotent stem cells; p53; Tumorigenicity
资金
- Ruth L. Kirschstein National Research Service Award [GM007185]
- Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Training Program
- California Institute for Regenerative Medicine (CIRM) Training Grant [TG2-01169]
- CIRM Awards [RB1-01397, RT3-07678]
- UC Discovery/NantWorks Biotechnology Award [178517]
- Air Force Office of Scientific Research [FA9550-15-1-0406]
- National Institutes of Health (NIH) [GM073981, CM156674, CA90571, GM114188, CA185189]
Human pluripotent stem cells (hPSCs) have great potential in regenerative medicine because they can differentiate into any cell type in the body. Genome integrity is vital for human development and for high fidelity passage of genetic information across generations through the germ line. To ensure genome stability, hPSCs maintain a lower rate of mutation than somatic cells and undergo rapid apoptosis in response to DNA damage and additional cell stresses. Furthermore, cellular metabolism and the cell cycle are also differentially regulated between cells in pluripotent and differentiated states and can aid in protecting hPSCs against DNA damage and damaged cell propagation. Despite these safeguards, clinical use of hPSC derivatives could be compromised by tumorigenic potential and possible malignant transformation from failed to differentiate cells. Since hPSCs and mature cells differentially respond to cell stress, it may be possible to specifically target undifferentiated cells for rapid apoptosis in mixed cell populations to enable safer use of hPSC-differentiated cells in patients. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据